BioArctic (BIOA) Q1 2026 earnings summary

Executive summary

• Q1 2026 delivered strong financial performance, driven by increased royalty income and milestone payments linked to global Leqembi sales, building on record 2025 results.

• Leqembi maintained global market leadership with robust sales growth, expanded patient access, and new long-term data showing sustained clinical benefit and high retention over four years.

• Project portfolio advanced with fully recruited phase IIa for exidavnemab, IND-enabling activities for BAN2238 and BAN3014, and progress in neurology and synucleinopathies.

• Partnerships with Eisai, Bristol Myers Squibb, and Novartis continued to deliver funding, R&D expertise, and milestone potential, with more collaborations anticipated.

• Patent portfolio comprised 22 families, 273 granted patents, and 156 pending applications as of March 2026.

Financial highlights

• Q1 2026 revenues were SEK 438 million, with royalty revenues from Leqembi up 68% year-over-year and milestone payments from Eisai totaling SEK 219 million (€20 million).

• Operating profit reached SEK 211 million, with net profit closely aligned at SEK 212 million after SEK 12 million in taxes.

• Cash, cash equivalents, and short-term investments exceeded SEK 2 billion at quarter-end, supporting ongoing investments and a proposed dividend.

• Operating expenses increased to SEK 207 million, mainly due to R&D investments.

• Q1 2025 net revenues included a one-time USD 100 million upfront from Bristol Myers Squibb, impacting year-over-year comparisons.

Outlook and guidance

• Eisai forecasts Leqembi sales of JPY 143.5 billion (~$910 million), implying 63% global growth for FY 2026.

• Operating costs for 2026 are expected to be 40%-60% higher than 2025, mainly due to R&D and portfolio expansion.

• Profitability is expected for the full year 2026, with future income generation seen as strong.

• Regulatory milestones anticipated for Leqembi subcutaneous initiation in the U.S., Japan, and China in 2026–2027.

• Continued expansion of the pipeline and further partnership milestones expected.